Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. filed a Form 8‑K on March 16, 2026 (Item 7.01) to disclose that the company has begun using an updated corporate presentation. The presentation is attached to the 8‑K as Exhibit 99.1 and the filing was signed by President and CEO Shawn K. Singh.

Key Details

• Filing date: March 16, 2026 (Form 8‑K).
• Disclosure type: Item 7.01 — Regulation FD Disclosure; Exhibit 99.1 = Vistagen Therapeutics, Inc. Corporate Presentation (dated March 2026).
• Signed by: Shawn K. Singh, President and Chief Executive Officer.
• No earnings, executive changes, mergers, or financial statements were reported in this filing beyond the exhibit listing (Item 9.01).

Why It Matters
Regulation FD disclosure means the company has made updated investor-facing materials publicly available so all investors have equal access to the information. While this filing does not contain financial results or operational changes, the new presentation may update the company’s strategic messaging, program status, timelines, or investor guidance—information investors often use to evaluate the company. Investors should review Exhibit 99.1 directly to see any substantive updates to Vistagen’s programs or corporate priorities.